Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arctic Bioscience AS (OSL:ABS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Arctic Bioscience AS's Enterprise Value for the quarter that ended in Dec. 2025 was kr151.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arctic Bioscience AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr-31.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arctic Bioscience AS EV-to-EBIT Related Terms
Arctic Bioscience AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Arctic Bioscience AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:ABS vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Arctic Bioscience AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arctic Bioscience AS EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Arctic Bioscience AS's EV-to-EBIT falls into.
Arctic Bioscience AS's current Enterprise Value is kr138.60 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arctic Bioscience AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr-31.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arctic Bioscience AS (OSL:ABS) has a EV-to-EBIT of -4.34 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Arctic Bioscience AS and its competitors. According to the industry distribution chart, Arctic Bioscience AS ranks #999999 out of 380 companies in the Biotechnology industry.
Is Arctic Bioscience AS's EV-to-EBIT too high?
Arctic Bioscience AS's current EV-to-EBIT is -4.34. Based on the distribution chart, Arctic Bioscience AS ranks #999999 out of 380 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arctic Bioscience AS has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arctic Bioscience AS's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arctic Bioscience AS ranks #999999 out of 380 companies for EV-to-EBIT. This places Arctic Bioscience AS in the lower half of its industry. The industry median EV-to-EBIT is 15.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.86, based on 380 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Arctic Bioscience AS and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arctic Bioscience AS's current EV-to-EBIT is -4.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arctic Bioscience AS stock overvalued right now?
Based on GuruFocus' analysis, Arctic Bioscience AS (OSL:ABS) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.10, compared to a current price of kr2.80 — trading 74.8% below its estimated fair value. The current EV-to-EBIT is -4.34. Arctic Bioscience AS's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Arctic Bioscience AS (OSL:ABS), the current EV-to-EBIT is -4.34 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arctic Bioscience AS (OSL:ABS) Overvalued in 2026?
Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued.
The current stock price of kr2.80 is trading 74.8% below its estimated GF Value™ of kr11.10.
GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.
Key valuation signals for OSL:ABS:
EV-to-EBIT: -4.34
GF Value™: kr11.10 vs. price of kr2.80 (74.8% below fair value)
No single metric tells the full story. See the OSL:ABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
54GF Score
Get the complete analysis for OSL:ABS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:ABS has been successfully added to your 
